Park Yong-jin opposes MFDS plan to classify GLP-1 drugs

Regulatory Review Reviews GLP-1 Misuse Classification in South Korea

The Regulatory Rationalization Committee has emerged as a variable in the Ministry of Food and Drug Safety’s plan to designate GLP-1 weight-loss drugs like Wegovy and Mounjaro as agents vulnerable to misuse and abuse, dailypharm.com reported.

The Tech TL;DR:

• South Korea’s Regulatory Rationalization Committee has intervened in the Ministry of Food and Drug Safety’s plan to classify GLP-1 weight-loss drugs under misuse-prone drug categories.

• Committee Vice Chairman Park Yong-jin publicly stated that grouping weight-loss therapies with erectile dysfunction medications or steroids is inappropriate without deeper review.

Regulatory Rationalization Committee Intervenes in Ministry Plans

The Ministry of Food and Drug Safety recently advanced a proposal to list prominent GLP-1 receptor agonists under its official misuse-and-abuse monitoring framework. That administrative push encountered immediate institutional pushback from the Regulatory Rationalization Committee. Park Yong-jin, vice chairman of the committee, posted a public statement on his social media channel challenging the designation. Park argued that applying the same regulatory categorization used for steroids and erectile dysfunction drugs to chronic weight-loss therapies lacks justification without a thorough examination of actual regulatory efficacy and potential adverse outcomes.

While acknowledging that off-label prescriptions and unauthorized distribution require strict administrative oversight, Park questioned whether slapping a misuse label on the pharmaceutical agents themselves serves as the optimal policy instrument. The World Health Organization classifies obesity as a chronic and relapsing disease, actively endorsing GLP-1 therapies as part of standard clinical care. South Korea’s proposed categorization diverges from international regulatory patterns, which typically prioritize clinical prescription controls and anti-counterfeiting enforcement over blanket classifications.

Weighing Patient Access Risks Against Illicit Distribution

The convergence of tighter customs blocking on overseas direct purchases and the proposed misuse designation has intensified anxieties regarding patient access to legitimate treatments. International regulatory bodies generally manage GLP-1 agents by enforcing strict supply-chain traceability and medical oversight within established healthcare infrastructure rather than creating blunt administrative deterrents.

Park emphasized that if the misuse label generates societal stigma and fear of the pharmaceutical treatment without effectively suppressing unauthorized consumption, the regulatory framework warrants reconsideration. The Regulatory Rationalization Committee intends to utilize its livelihood subcommittee to review the Ministry’s evidentiary basis, international administrative precedents, and feedback from medical professionals and patient advocacy groups.